BiotechTube

Zagotenemab + Placebo

Phase 2Completed
1 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Alzheimer Disease (AD)

Conditions

Alzheimer Disease (AD)

Trial Timeline

Apr 30, 2018 → Oct 25, 2021

NCT ID
NCT03518073

About Zagotenemab + Placebo

Zagotenemab + Placebo is a phase 2 stage product being developed by Eli Lilly for Alzheimer Disease (AD). The current trial status is completed. This product is registered under clinical trial identifier NCT03518073. Target conditions include Alzheimer Disease (AD).

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer Disease (AD) were approved

Approved (20) Terminated (2) Active (0)
✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved
✅DonepezilEisaiApproved
✅DONEPEZIL HYDROCHLORIDEEisaiApproved
✅Donepezil HCLEisaiApproved
✅Donepezil HClEisaiApproved
✅Donepezil HydrochlorideEisaiApproved
✅AriceptEisaiApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03518073Phase 2Completed

Competing Products

20 competing products in Alzheimer Disease (AD)

See all competitors
ProductCompanyStageHype Score
[18F]NAV4694Navidea BiopharmaceuticalsPhase 2
21
Bromocriptine Mesilate + PlacebosTowa PharmaceuticalPhase 1/2
32
LY450139 + PlaceboEli LillyPhase 3
40
Solanezumab + PlaceboEli LillyPhase 3
32
LY450139 dihydrate + placeboEli LillyPhase 2
35
Donanemab + Placebo + LY3202626Eli LillyPhase 2
35
Donanemab + PlaceboEli LillyPhase 3
47
GSK4527226AlectorPhase 2
29
AL002 + PlaceboAlectorPhase 2
25
GSK4527226AlectorPhase 2
32
AL002AlectorPhase 2
17
Solanezumab + PlaceboEli LillyPhase 3
32
donanemabEli LillyPhase 2
35
ATH-1017LeonaBioPhase 2/3
20
ATH-1017 + PlaceboLeonaBioPhase 2/3
28
ATH-1017 + PlaceboLeonaBioPhase 2
25
NDX-1017 + PlaceboLeonaBioPhase 1
19
simufilamCassava SciencesPhase 2
17
50 mg PTI-125 + 100 mg PTI-125 + 200 mg PTI-125Cassava SciencesPhase 1
19
Placebo oral tablet + Simufilam 100 mg tablet + Simufilam 50 mg oral tabletCassava SciencesPhase 2
25